Study Information

Study Title

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Study Summary

The purpose of this prospective, longitudinal, non-interventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF). National Cancer Institute-Molecular Analysis for Therapy Choice, known as NCI-MATCH or study EAY131, is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.Precision medicine refers to the tailoring of treatment based on the characteristics of each individual. Treatment focuses on molecular abnormalities instead of the organ site of the cancer.NCI-MATCH was co-developed by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute.NCI-MATCH is considered the largest precision medicine cancer trial to date based on the number of patients, treatment options, and types of cancer being studied in a single clinical trial About 5000 patients will receive genetic testing to identify those eligible for one of 24 or more treatment optionsThe 24 or more treatment options explore a large number of genetic abnormalities and drugs—far more than any other cancer trialIt includes a large number of cancer types (most other trials address a single cancer) and has many more drugs available than most other cancer trialsA network of four molecular diagnostics laboratories provides capacity for the large number of patients There is about a 20% chance of “matching” to a trial.

Principal Investigator

Dr. Kenneth Blankstein

Phase II Disease

Eligible Locations

• Advanced solid tumors Lymphomas Inclusion Patients must be 18 years of age or older.
• Any type of solid tumor or lymphoma (cancer in the cells of the immune system) that has returned or gotten worse after standard systemic therapy (oral or intravenous).
• Patients may also be eligible if they have a rare type of cancer for which there is no standard treatment.

NOTE: The inclusion and exclusion criteria for this study may be confusing, so if you are having a hard time deciding if you may be eligible, feel free to contact us!

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.

This Study is now Closed